Predictors of Nodal and Metastatic Failure in Early Stage Non–small-cell Lung Cancer After Stereotactic Body Radiation Therapy

Alberto Cerra-Franco, Sheng Liu, Michella Azar, Kevin Shiue, Samantha Freije, Jason Hinton, Christopher R. Deig, Donna Edwards, Neil C. Estabrook, Susannah G. Ellsworth, Ke Huang, Khalil Diab, Mark P. Langer, Richard Zellars, Feng Ming Kong, Jun Wan, Tim Lautenschlaeger

Research output: Contribution to journalArticle

Abstract

Many patients with early stage non–small-cell lung cancer develop metastases after stereotactic body radiation therapy. We retrospectively analyzed multiple variables in 406 lesions to develop a predictor for metastatic failure. Gross tumor volume and prescription dose were significantly associated with metastases. A metastasis risk score tool was developed to identify patients at higher risk for metastases after lung stereotactic body radiation therapy who might benefit from enrollment in future trials evaluating the benefit of adjuvant or intensified treatment.

Original languageEnglish (US)
Pages (from-to)186-193.e3
JournalClinical Lung Cancer
Volume20
Issue number3
DOIs
StatePublished - May 2019

    Fingerprint

Keywords

  • Metastasis
  • SABR
  • SBRT
  • Stereotactic body ablative radiotherapy
  • Stereotactic body radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Cerra-Franco, A., Liu, S., Azar, M., Shiue, K., Freije, S., Hinton, J., Deig, C. R., Edwards, D., Estabrook, N. C., Ellsworth, S. G., Huang, K., Diab, K., Langer, M. P., Zellars, R., Kong, F. M., Wan, J., & Lautenschlaeger, T. (2019). Predictors of Nodal and Metastatic Failure in Early Stage Non–small-cell Lung Cancer After Stereotactic Body Radiation Therapy. Clinical Lung Cancer, 20(3), 186-193.e3. https://doi.org/10.1016/j.cllc.2018.12.016